MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40259-017-0232-7

Медицинская библиотека · BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2017

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.

Yoo Dae Hyun, Suh Chang-Hee, Shim Seung Cheol, Jeka Slawomir, Molina Francisco Fidencio Cons, Hrycaj Pawel, Wiland Piotr, Lee Eun Young, Medina-Rodriguez Francisco G, Shesternya Pavel, Radominski Sebastiao, Stanislav Marina, Kovalenko Volodymyr, Sheen Dong Hyuk, Myasoutova Leysan, Lim Mie Jin, Choe Jung-Yoon, Lee Sang Joon, Lee Sung Young, Kim Sung Hwan, Park Won

Клиническое исследование I фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

CT-P10 is a biosimilar of innovator rituximab (RTX), a biological therapy used to treat patients with rheumatoid arthritis (RA) who have responded inadequately to anti-tumor necrosis factor agents.

OBJECTIVE

Our objective was to compare the clinical profile of CT-P10 versus RTX in patients with RA who received up to two courses of treatment and were followed for up to 72 weeks.

METHODS

In this multicenter double-blind phase I study, patients were randomized 2:1 to receive CT-P10 1000 mg or RTX 1000 mg at weeks 0 and 2. Based on disease activity, patients could receive a second course of treatment between weeks 24 and 48. Efficacy endpoints, including mean change from baseline in Disease Activity Score using 28 joints (DAS28), safety, immunogenicity, pharmacokinetics, and pharmacodynamics were evaluated.

RESULTS

In total, 154 patients were randomized to CT-P10 or RTX (n = 103 and 51, respectively); 137 (n = 92 and 45) completed the first course of treatment, of whom 83 (n = 60 and 23) were re-treated. Improvements from baseline in all efficacy endpoints were highly similar between the CT-P10 and RTX groups over both treatment courses. At week 24 after the second course, mean change from week 0 of the first course in DAS28 erythrocyte sedimentation rate was -2.47 and -2.04 for CT-P10 and RTX, respectively, (p = 0.1866) and in DAS28 C-reactive protein was -2.32 and -2.00, respectively (p = 0.3268). The proportion of patients positive for antidrug antibodies at week 24 after the second treatment course was 20.0% and 21.7% in the CT-P10 and RTX groups, respectively. The safety profile of CT-P10 was comparable to that of RTX, and pharmacokinetic and pharmacodynamic properties were similar.

CONCLUSIONS

In patients with RA, efficacy, safety, and other clinical data were comparable between CT-P10 and RTX after up to two courses of treatment over 72 weeks. (ClinicalTrials.gov identifier NCT01534884).

Для цитирования: Yoo Dae Hyun, Suh Chang-Hee, Shim Seung Cheol, Jeka Slawomir, Molina Francisco Fidencio Cons, Hrycaj Pawel, Wiland Piotr, Lee Eun Young, Medina-Rodriguez Francisco G, Shesternya Pavel, Radominski Sebastiao, Stanislav Marina, Kovalenko Volodymyr, Sheen Dong Hyuk, Myasoutova Leysan, Lim Mie Jin, Choe Jung-Yoon, Lee Sang Joon, Lee Sung Young, Kim Sung Hwan, Park Won. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2017. DOI: 10.1007/s40259-017-0232-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.